Refractory Malignant Solid Neoplasm Recruiting Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0088735 (Refractory Malignant Solid Neoplasm)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening
NCT03213691Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Treatment